Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism: A Review of the RIETE Registry

Clinical and Applied
Thrombosis/Hemostasis
2014, Vol. 20(8) 772-778
© The Author(s) 2014
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1076029614532008
cat.sagepub.com

Lauren P. Cote, RN, BSN, CCRN¹, Steven Greenberg, MD²,
Joseph A. Caprini, MD, MS, FACS³, James Stone, MD, FACS⁴,
Juan I. Arcelus, MD, PhD⁵, Luciano López-Jiménez, MD⁶,
Vladimir Rosa, MD⁷, Sebastian Schellong, MD, PhD⁸, and
Manuel Monreal, MD, PhD⁹; the RIETE Investigators

Abstract

Objectives: Registro Informatizado de Enfermedad TromboEmbólica (RIETE) database was used to investigate whether neurosurgical patients with venous thromboembolism (VTE) were more likely to die of bleeding or VTE and the influence of anticoagulation on these outcomes. **Methods:** Clinical characteristics, treatment details, and 3-month outcomes were assessed in those who developed VTE after neurosurgery. **Results:** Of 40 663 patients enrolled, 392 (0.96%) had VTE in less than 60 days after neurosurgery. Most patients in the cohort (89%) received initial therapy with low-molecular-weight heparin, (33% received subtherapeutic doses). In the first week, 10 (2.6%) patients died (8 with pulmonary embolism [PE], no bleeding deaths; $P = .005$). After the first week, 20 (5.1%) patients died (2 with fatal bleeding, none from PE). Overall, this cohort was more likely to develop a fatal PE than a fatal bleed (8 vs 2 deaths, $P = .058$). **Conclusions:** Neurosurgical patients developing VTE were more likely to die from PE than from bleeding in the first week, despite anticoagulation.

Keywords

venous thromboembolism, anticoagulants, bleeding, pulmonary embolism

Introduction

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the neurosurgical population.¹⁻⁶ These patients, in particular, have the following notable risk factors for VTE: intracranial surgery, prolonged length of procedures, malignancy, weakness or paresis, and advanced age.^{4,6-9} Current guidelines from the American College of Chest Physicians recommend that patients with acute VTE be treated initially with low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux, followed by long-term treatment with vitamin K antagonists (VKAs).¹⁰ However, there is uncertainty about the optimal therapy in patients with VTE who underwent recent neurosurgery, as they are often excluded from randomized clinical trials of anticoagulant therapy.⁹ These patients are perceived to be at substantial risk of rebleeding if therapy with anticoagulants is prescribed, yet they are at increased risk of recurrent VTE and/or pulmonary embolism (PE) in the absence of treatment.

The Registro Informatizado de Enfermedad TromboEmbólica (RIETE; or in English: Computerized Registry of Patients With Venous Thromboembolism) initiative is an ongoing, multicenter, international (Spain, Argentina, Belgium, Brazil,

¹ Department of Nursing/Critical Care, Evanston Hospital, NorthShore University HealthSystem, Chicago, IL, USA

² Department of Anesthesia/Critical Care, Evanston Hospital, NorthShore University HealthSystem, Chicago, IL, USA

³ Division of Vascular Surgery, Evanston Hospital, NorthShore University HealthSystem, Chicago, IL, USA

⁴ Department of Neurosurgery, Evanston Hospital, NorthShore University HealthSystem, Chicago, IL, USA

⁵ Department of General Surgery, Hospital Universitario Virgen de las Nieves, Granada, Spain

⁶ Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain

⁷ Department of Internal Medicine, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

⁸ Department of Internal Medicine, Municipal Hospital of Dresden Friedrichstadt, Dresden, Germany

⁹ Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

Corresponding Author:

Lauren P. Cote, Department of Nursing/Critical Care, NorthShore University HealthSystem, Evanston Hospital, 2650 Ridge Ave Evanston, IL, USA.
Email: lcotemx3@sbcglobal.net; lcote@northshore.org

Canada, Czech Republic, Ecuador, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Republic of Macedonia, Switzerland, and the United States enroll patients) observational registry of consecutive patients with symptomatic, objectively confirmed, acute VTE.¹¹⁻¹⁵ Since its inception, RIETE was designed to gather data on the clinical characteristics, treatment patterns, and outcomes in patients with VTE. The present study utilized the RIETE cohort to investigate whether VTE is a major cause of morbidity and mortality in the neurosurgical intracranial- and spinal-operated population. The main objectives were to understand the natural history of postoperative VTE in neurosurgical patients as well as to determine the risk benefit ratio of treating these patients with anticoagulation.

Methods

We assessed the clinical characteristics, treatment details, and 3-month outcome in those who developed VTE in less than 60 days after intracranial and/or spinal neurosurgery in the RIETE database. Venous thromboembolism was confirmed by objective tests (contrast venography or full leg compression ultrasonography for suspected deep vein thrombosis [DVT]; pulmonary angiography, lung scintigraphy, or helical computed tomography scan). Patients were excluded if they were currently participating in a therapeutic clinical trial. This analysis was approved by the Institutional Review Board of NorthShore University HealthSystem (Evanston, Illinois). All patients (or their legal power of attorney if indicated) provided written consent for their participation in the registry.

Study Design

All neurosurgical patients in RIETE, with acute VTE in less than 60 days after intracranial or spinal surgery, were evaluated. The major outcomes included the development of fatal PE or fatal bleeding during the first 90 days after the diagnosis of VTE. Secondary outcomes included major bleeding and VTE recurrences. The causes of death were determined by the attending physicians. Fatal PE, in the absence of autopsy, was defined as any death appearing in less than 7 days after PE diagnosis, in the absence of an alternative cause of death. Fatal bleeding was defined as any death occurring in less than 7 days after a major bleeding episode. Bleeding complications were classified as "major" if they were overt and required a transfusion of 2 units of blood or more, were retroperitoneal, spinal, or intracranial, or if they were fatal.

Study Variables and Definitions

The following parameters were recorded when the qualifying episode of VTE was diagnosed: patient's sex, age, and body weight; chronic heart or lung disease; additional risk factors for VTE; laboratory data on admission; anticoagulant treatment; and outcomes during the first 3 months of VTE therapy.

Follow-Up

Patients were managed according to the clinical practice of each participating hospital and were not subject to any pre-determined intervention. During follow-up, special attention was paid to any signs or symptoms suggesting recurrent VTE or bleeding complications. Each episode of clinically suspected recurrent DVT or PE required documentation by repeat ultrasonography, venography, lung scanning, helical computed tomography (CT) scan, or pulmonary angiography.

Data Collection and Monitoring

The primary investigator made sure that eligible patients were consecutively enrolled. Data were recorded onto a computer-based case report form at each participating hospital and submitted to a centralized coordinating center through a secure Web site. Encryption of data was used to enhance confidentiality and security. Data quality was regularly monitored and documented electronically to detect inconsistencies or errors. Data quality was also monitored by periodic visits to participating hospitals, by contract research organizations, which compared the medical records with the Web database. Patient identities remained confidential and were identified by a unique number assigned by the study coordinating center responsible for the data management.

Statistical Analysis

Mann-Whitney *U* test and Student *t* test were used to compare continuous variables. Categorical variables were compared by the Fisher exact test, and the odds ratios and corresponding 95% confidence intervals were calculated. Survival curves were constructed according to the Kaplan-Meier method. SPSS software (version 15, SPSS Inc Chicago, Illinois) was used for statistical management of the data.

Results

Of the total 40 663 patients with symptomatic VTE in the RIETE database, 392 (0.96%) had VTE within 60 days following a neurosurgical procedure. Of these, 140 (36%) patients underwent oncologic surgery (116 with brain cancer, 9 lung, 4 breast, 4 prostate, 2 colorectal, 2 bladder, 2 kidney, and 10 other). A total of 60 (15%) patients were operated on because of cerebral bleeding and 192 (49%) patients had other reasons for surgery (34 with hernia repair, 25 meningioma, 11 other benign tumors, 13 chronic subdural hematoma, 8 lumbar channel stenosis repair, 8 arteriovenous malformation, 5 cerebral biopsy, 5 valvuloperitoneal derivation, and 75 not reported). Table 1 depicts the differences in clinical characteristics of patients having malignancy in brain or spine or intracranial hemorrhage surgeries or other surgeries. A total of 198 (51%) patients presented with PE (with or without concomitant DVT) and 194 patients presented with DVT alone.

Patients with malignancies were more likely to receive corticosteroids than those in the other groups (41% vs 15% and

Table 1. Differences in Clinical Characteristics Between Patients Having Malignancy of Brain or Spine Versus Intracranial Hemorrhage and Other Intracranial or Spine Surgeries.^a

	Malignancy—Brain or Spine	Intracranial Hemorrhage	Other Intracranial or Spine
Patients, N	140	60	192
Clinical characteristics			
Gender (male)	85 (61%)	41 (68%)	92 (48%) ^b
Mean age, years $\pm$ SD	61 $\pm$ 13	68 $\pm$ 14 ^c	59 $\pm$ 15
Body weight, kg $\pm$ SD	76 $\pm$ 13	73 $\pm$ 13	75 $\pm$ 15
Underlying conditions			
Chronic lung disease	6 (4.3%)	4 (6.7%)	9 (4.7%)
Chronic heart failure	2 (1.4%)	5 (8.3%) ^b	3 (1.6%)
Creatinine levels > 1.2 mg/dL	10 (7.1%)	5 (8.3%)	5 (2.6%) ^b
Additional risk factors for VTE			
Estrogen therapy	1 (0.7%)	0	4 (2.1%)
Pregnancy/postpartum	0	0	1 (0.5%)
Recent travel	0	1 (1.7%)	1 (0.5%)
Cancer	140 (100%)	9 (15%) ^c	0 ^c
Prior VTE	11 (7.9%)	4 (6.7%)	7 (3.6%)
Concomitant therapies			
Antiplatelet drugs	6 (4.5%)	6 (13%)	10 (5.7%)
Corticosteroids	54 (41%)	7 (15%) ^d	20 (11%) ^c
NSAIDs	3 (2.3%)	5 (10%) ^b	16 (9.1%) ^b
VTE prophylaxis			
Yes	62 (44%)	17 (28%) ^b	76 (40%)
Low-molecular-weight heparin	53 (93%)	13 (93%)	69 (97%)
Mean LMWH dose per day	4699 $\pm$ 3490	3415 $\pm$ 788	4244 $\pm$ 1821
Duration, days $\pm$ SD	14 $\pm$ 10	11 $\pm$ 10	13 $\pm$ 12
Initial VTE presentation			
Time to VTE, days $\pm$ SD	27 $\pm$ 17	20 $\pm$ 13 ^b	25 $\pm$ 17
Pulmonary embolism	86 (61%)	16 (27%)	96 (50%)
For patients with PE			
SBP levels < 100 mm Hg	11 (13%)	7 (44%) ^d	18 (19%)
Heart rate > 110 bpm	28 (22%)	6 (10%)	22 (13%) ^b
Sat O ₂ < 90%	23 (27%)	2 (13%)	21 (22%)
For patients with isolated DVT	54	44	96
Proximal DVT	34 (63%)	29 (66%)	69 (72%)
Upper-extremity DVT	2 (3.7%)	4 (9.1%)	6 (6.3%)

Abbreviations: SD, standard deviation; VTE, venous thromboembolism; NSAID, nonsteroid anti-inflammatory drugs; SBP, systolic blood pressure; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; DVT, deep vein thrombosis.

^aDifferences between patients with malignancies and those undergoing other types of surgery.

^b $P < .05$.

^c $P < .001$.

^d $P < .01$.

11%, respectively; $P < .01$) but less likely to receive nonsteroidal anti-inflammatory drugs (2.3% vs 10% and 9.1%, respectively; $P < .05$). Those with recent intracranial hemorrhage were less likely to have received pharmacological VTE prophylaxis (28% vs 44% and 44%, respectively; $P < .05$; Table 1). Moreover, patients with intracranial hemorrhage were less likely to present with an acute PE when compared to patients with malignancies (27% vs 61%, $P < .001$; or 50% in the “other brain and spinal reasons” group, $P = .001$). Most (89%) patients in the 3 subgroups received initial therapy with LMWH (114 of 348 received subtherapeutic LMWH doses <170 IU/kg/d), and a vena cava filter was inserted in 44 (11%) patients (Table 2). Patients undergoing surgery for intracranial hemorrhage received lower doses of LMWH both for initial therapy (148 $\pm$ 60 IU/kg/d vs 168 $\pm$ 52 and 169 $\pm$ 42,

respectively; $P < .05$) and for long-term therapy (124 $\pm$ 54 IU/kg/d vs 150 $\pm$ 47 and 150 $\pm$ 48, respectively; $P < .001$). A total of 127 (32%) patients received long-term therapy with VKA drugs and 249 (64%) received LMWH. A larger amount of patients undergoing surgery for “other brain and spinal reasons” received long-term therapy with VKA drugs (Table 2).

During the first week of VTE therapy, 10 patients died: 8 died of PE (6 died of the initial event and 2 died of recurrent PE) and 2 died of other reasons (1 due to respiratory insufficiency and 1 heart failure). No patients died of intracranial or spinal bleeding. At the 90-day follow-up, it was found that of the patients undergoing surgery for malignancy, there were 16 deaths (3 due to fatal PE and 1 fatal bleeding). Among those operated on because of prior intracranial hemorrhage, there were 6 deaths (50% of them died of PE), and among those

Table 2. Differences in Treatment Strategies and 3-Month Outcomes Between Patients With Malignancies Versus Intracranial Hemorrhage and Other Intracranial or Spinal Surgeries.^a

	Malignancy—Brain or Spine	Intracranial Hemorrhage	Other Intracranial or Spine
Patients, N	140	60	192
Initial therapy			
No drugs during the first 5 days	1 (0.7%)	1 (1.7%)	0
Unfractionated heparin	9 (6.4%)	5 (8.3%)	19 (9.9%)
Low-molecular-weight heparin	103 (74%)	41 (68%)	133 (69%)
Mean LMWH dose, IU/kg/d	168 ± 52	148 ± 60 ^b	169 ± 42
Thrombolytics	1 (0.7%)	0	0 ^c
Inferior vena cava filter	15 (11%)	14 (23%) ^b	15 (7.8%)
Long-term treatment (3 months)			
Low-molecular-weight heparin	104 (74%)	47 (78%)	98 (51%) ^c
Mean LMWH dose, IU/kg/d	150 ± 47	124 ± 54 ^d	150 ± 48
Vitamin K antagonists	32 (23%)	8 (13%)	87 (45%) ^c
90-day outcome			
Major bleeding	4 (2.9%)	1 (1.7%)	7 (3.6%)
Recurrent DVT	2 (1.4%)	2 (3.3%)	2 (1.0%)
Recurrent PE	5 (3.6%)	2 (3.3%)	3 (1.6%)
Recurrent VTE	7 (5.0%)	4 (6.7%)	5 (2.6%)
Overall death	16 (11%)	6 (10%)	4 (2.1%) ^c
Causes of death			
Fatal bleeding	1 (0.7%)	0	1 (0.5%)
Fatal PE	3 (2.1%)	3 (5.0%)	2 (1.0%)
Fatal, initial PE	1 (0.7%)	2 (3.3%)	2 (1.0%)
Fatal, recurrent PE	2 (1.4%)	1 (1.7%)	—
Sudden, unexplained	0	0	0
Respiratory insufficiency	1 (0.7%)	0	0
Disseminated malignancy	9 (6.4%)	1 (1.7%)	0 ^c
Other	2 (1.4%)	2 (3.3%)	1 (0.5%)

Abbreviations: LMWH, low-molecular-weight heparin; IU, international units; DVT, deep vein thrombosis; PE, pulmonary embolism; NS, nonsignificant.

^aDifferences between patients with malignancies, intracranial hemorrhage, and those undergoing other intracranial or spinal surgery.

^b*P* < .05.

^d*P* < .01.

^c*P* < .001.

patients undergoing surgery for “other brain and spinal reasons,” there were 4 deaths (2 with PE and 1 with intracranial bleeding). Of the 8 patients dying of PE, 4 were receiving LMWH doses > 150 IU/kg/d, 2 had an inferior vena cava (IVC) filter plus subtherapeutic (<150 IU/kg/d) LMWH, and 2 were on UFH (mean doses, 366.67 u/kg/d).

After the first week (Tables 3 and 4), 20 patients died: 2 died of intracranial hemorrhage and none died of PE (new onset or recurrent). In addition, 9 patients had recurrent VTE (5 with PE and 4 with DVT) and 9 had major bleeding (2 with fatal, 4 intracranial hemorrhage, 2 muscular hematoma, 1 gastrointestinal, 1 retroperitoneal, and 1 other). Of the 9 patients with recurrent VTE, 4 were receiving LMWH doses <150 IU/kg/d, and 2 of the 6 patients had recurrent PE, despite prior insertion of a vena cava filter. Despite the mentioned differences in initial and long-term therapy between patients in the 3 subgroups, there were no significant differences in the 90-day rate of fatal PE, recurrent VTE, or major bleeding. However, those undergoing surgery for “other brain and spinal reasons” had a lower mortality rate (2.1% vs 11% and 10%, respectively; *P* < .001). Overall, PE was the most common cause of death within the first week (8 deaths due to PE

and no fatalities due to bleeding), despite variable doses of anticoagulation.

Discussion

Treatment decisions in neurosurgical patients who subsequently develop VTE are often made on an empirical, individual basis, including evaluating the expected morbidity and mortality associated with different treatment options. The findings in the current study reveal that many of these patients received initial therapy at lower than recommended doses of heparin, most likely due to the concern that many physicians may feel for the risk of bleeding. Interestingly, however, we found that the rate of fatal PE exceeded the rate of fatal bleeding, particularly within the first week of therapy. All 8 patients with fatal PE in our series died during the first week after diagnosis of VTE. This included 4 patients receiving therapeutic anticoagulation and 2 patients with a vena cava filter. Although these interventions are important, deaths still occur. The absence of rebleeding or deaths from hemorrhage during the first week, despite the use of anticoagulants, is likely the most interesting finding in this study.

Table 3. Clinical Characteristics and Current Therapy in 18 Patients Who Presented With Acute PE and Developed Adverse Events During Outcome.

Reason for Surgery	Days From Surgery to VTE	Days From VTE to the Event	Type of Event	Current Therapy	Daily, doses/kg	IVC Filter
Malignancy	23	1	Fatal PE	LMWH	202	No
Intracranial hemorrhage	17	1	Fatal PE	UFH	No data	No
Intracranial hemorrhage	18	1	Fatal PE	LMWH	198	No
Laminectomy	5	1	Major bleeding	LMWH	93	Yes
Chronic SH	66	2	Fatal PE	LMWH	73	No
Other surgery, NS	70	3	Fatal PE	LMWH	165	No
Other surgery, NS	22	5	Major bleeding	LMWH	48	No
Brain abscess	7	5	Recurrent DVT	LMWH	187	No
Malignancy	9	6	Fatal, recurrent PE	LMWH	195	No
Meningioma	No data	12	Fatal bleeding	LMWH	197	Yes
Malignancy	8	11	Recurrent PE	LMWH	121	Yes
Intracranial hemorrhage	24	12	Major bleeding	LMWH	107	No
Malignancy	23	15	Major bleeding	LMWH	190	No
Laminectomy	9	27	Recurrent PE	AVK	—	No
Malignancy	No data	30	Major bleeding	LMWH	169	Yes
Malignancy	29	32	Major bleeding ^a	LMWH	77	Yes
Brain abscess	36	44	Major bleeding	AVK	—	No
Malignancy	21	47	Recurrent DVT	AVK	—	Yes

Abbreviations: VTE, venous thromboembolism; SH, subdural hematoma; NS, not specified; PE, pulmonary embolism; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; IU, international units; IVC, inferior vena cava; AVK, antivitamin K.

^a This patient had a recurrent DVT 3 days after discontinuing anticoagulation due to the bleeding event.

Table 4. Clinical Characteristics and Current Therapy in 12 Patients Who Presented With Acute DVT and Developed Adverse Events During Outcome.

Cause of surgery	Days From Surgery to VTE	Days From VTE to the Event	Type of Event	Current Therapy	Daily Doses/kg	IVC Filter
Intracranial hemorrhage	10	2	Fatal, recurrent PE	UFH	367	No
Ventricular drainage	4	4	Major bleeding	LMWH	55	No
Malignancy	6	5	Fatal, recurrent PE	LMWH	52	Yes
Malignancy	31	8	Recurrent PE	LMWH	145	Yes
Malignancy	9	11	Recurrent PE	LMWH	185	Yes
Intracranial hemorrhage	7	11	Recurrent DVT	LMWH	76	Yes
Intracranial hemorrhage	21	12	Major bleeding	UFH	286	Yes
Other surgery, NS	7	17	Major bleeding	LMWH	59	Yes
A-V malformation	40	28	Recurrent PE	AVK	—	No
Malignancy	18	31	Fatal bleeding	LMWH	177	No
Stereotactic biopsy	35	58	Recurrent DVT	AVK	—	No
Intracranial hemorrhage	3	63	Recurrent DVT	LMWH	39	No

Abbreviations: AVK, antivitamin K; A-V, arteriovenous; DVT, deep vein thrombosis; IU, international units; IVC, inferior vena cava; LMWH, low-molecular-weight heparin; NS, not specified; PE, pulmonary embolism; SH, subdural hematoma; UFH, unfractionated heparin; VTE, venous thromboembolism.

Unexpectedly, major bleeding was the main threat beyond the first week after VTE diagnosis. Our incidence of intracranial rebleeding during the first week of anticoagulant therapy may seem unexpectedly low, but most patients received lower than recommended doses of heparin. After the first week of therapy, there were 2 fatal bleeds and no more fatal PEs, probably because clinicians increased anticoagulation for those patients who did not bleed during the first week. Literature has repeatedly revealed a consistent finding that neurosurgical patients have a statistically significant reduction in VTE development with pharmacologic VTE prophylaxis, insignificant association

of an increase in ICH, but a statistically significant doubling of “minor” bleeding.^{16,17} Many of these high-risk patients have a vena cava filter placed instead of anticoagulation. In our series, we recorded 2 PE deaths with filters in place and 2 recurrent nonfatal PEs in patients with filters. According to Leon et al, the incidence of complications related to the presence of an IVC filter in high-risk patients may be as high as 22%, with some of the events resulting in significant morbidity.¹⁸

Several studies show that pharmacologic prophylaxis is not used routinely for neurosurgical patients due to physician perception of a heightened risk of intracranial hemorrhage.^{14,15,19}

In our patient cohort, there were 140 patients with malignancy (53 of which received LMWH prophylaxis) and 60 patients diagnosed with an intracerebral hemorrhage (13 of which received LMWH prophylaxis). Of these patients with malignancies and intracranial hemorrhage who had received pharmacologic prophylaxis, the patients with intracranial hemorrhage were less likely to present with an acute PE (27%) than those for malignancy surgery (61%; $P < .05$). The patients with intracranial hemorrhage received less anticoagulation but were found to present with acute PE less than that of patients with malignancy.

There are several limitations to our study. First, this was a retrospective analysis of patients consecutively recruited, which is subject to selection bias. Second, the small sample size and limited associated outcomes do not allow for broad-based recommendations on managing these patients. Third, the types of treatment and dosing of anticoagulation were not standardized in our patient cohort. Therefore, we do not know which type and dose of anticoagulation is most efficacious in reducing adverse events such as a fatal VTE. Fourth, specifications of types and dosing of pharmacologic prophylaxis and mechanical prophylaxis were not described in the RIETE cohort of neurosurgical patients. Fifth, patients in the RIETE cohort were selected from several countries. Practice variability among different countries may affect the outcomes determined by the study. For example, the timing and dosing of prophylaxis can vary depending on the individual country's practice pattern, underlying disease, and presence or absence of malignancy. Furthermore, the data reported from RIETE were entered into the registry by a variety of practitioners. This process may lend itself to inaccuracies in data reporting. Finally, the lack of neurosurgical data in RIETE limits the quality of this study. It would be interesting to know more details on the interventions; on how many patients underwent a new CT scan of the brain after anticoagulant treatment was started and the proportion of those with hematoma enlargement; whether there were any changes in the neurological function; and how many patients received prohemostatic agents after surgery. A further breakdown of the categories of malignancy would be of interest such as brain versus spine and within the brain as to the type of malignancy (primary vs metastatic). Also of interest would be a breakdown of patient immobility features such as hemiplegia or paraplegia and lethargy/coma predisposing to VTE.

Despite various VTE treatment plans in the patients undergoing neurosurgery of brain and spine, fatal VTEs are still prevalent. This RIETE analysis revealed that a neurosurgical patient is more likely to die of a fatal VTE, within the first week after VTE diagnosis, than a fatal bleed, particularly within the first week after VTE diagnosis. Further research is required regarding the dosage, types, and timing of pharmacologic prophylaxis and whether these variables play a role in reducing the incidence of fatal PEs in neurosurgical patients.

In summary, the clinical impact of VTE in the patients undergoing neurosurgery of brain and spine is considerable. During the first week after detecting VTE, the main threat is fatal PE (Figure 1, P value .005); beyond the first week, the

Figure 1. Cumulative incidence of events. P value of fatal pulmonary embolism (PE) within the first 7 days after venous thromboembolism (VTE) diagnosis, compared to fatal PE after 7 days, was .005. P value of fatal PE compared to fatal bleeding was .433. There was no difference in the P value of fatal PE compared to fatal bleeding. P value of recurrent VTE compared to major bleeding was .058. There was a trend found when comparing recurrent VTE to major bleeding.

main threat is bleeding. Future randomized controlled trials may clarify the benefits of different therapeutic options in this population.

Appendix

Members of the RIETE Group

SPAIN: Arcelus JJ, Ballaz A, Barba R, Barrón M, Barrón-Andrés B, Bascuñana J, Bedate P, Blanco-Molina A, Bueso T, Casado I, Conget F, del Molino F, del Toro J, Falgá C, Fernández-Capitán C, Font C, Fuentes MI, Gallego P, García-Bragado F, Gavín O, Gómez V, González J, González-Bachs E, Grau E, Guil M, Guijarro R, Gutiérrez J, Hernández L, Hernández-Huerta S, Jara-Palomares L, Jaras MJ, Jiménez D, Lobo JL, López-Jiménez L, López-Sáez JB, Lorenzo MA, Lorenzo A, Luque JM, Madridano O, Macià M, Maestre A, Marchena PJ, Martín M, Monreal M, Mora JM, Mosquera D, Muñoz FJ, Nauffal MD, Nieto JA, Núñez MJ, Ogea JL, Otero R, Pedrajas JM, Peris ML, Raissouni N, Riera-Mestre A, Rivas A, Rodríguez-Dávila MA, Román P, Rosa V, Ruiz J, Ruiz-Ribó MD, Ruiz-Garnieta A, Ruiz-Giménez N, Sahuquillo JC, Samperiz A, Sánchez Muñoz-Torrero JF, Soler S, Tiberio G, Tilvan RM, Tolosa C, Trujillo J, Uresandi F, Valdés M, Valero B, Valle R, Vela J, Villalobos A, Villalta J, CZECH REPUBLIC: Malý R, Hirmerova J, FRANCE: Bertolletti L, Bura-Riviere A, Farge-Bancel D, Grange C, Hij A, Mahe I, Merah A, Quere I, GERMANY: Schellong S, GREECE: Babalis D, Papadakis M, Tzinieris I, ISRAEL: Braester A, Brenner B, Tzoran I, Zeltser D, ITALY: Barillari G, Ciammaichella M, Di Micco P, Duce R, Pasca S, Pesavento R, Piovella C, Poggio R, Prandoni P, Quintavalla R, Rocci A, Rota L, Schenone A, Tiraferri E, Tonello D, Tufano A, Visonà

A, Zalunardo B, PORTUGAL: Barbosa AL, Gonçalves F, Rodrigues AM, Santos M, Saraiva M, REPUBLIC OF MACEDONIA: Bosevski M, Kovacevic D, SWITZERLAND: Alatri A, Aujeski D, Bounameaux H, Calanca L, Mazzolai L. USA: Caprini J.

Acknowledgments

We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG's support was limited to the part of RIETE outside Spain, which accounts for a 18.86% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S & H Medical Science Service, for their quality control, logistic, and administrative support and Professor Salvador Ortiz, Universidad Autónoma de Madrid and Statistical Advisor S & H Medical Science Service, for the statistical analysis of the data presented in this article.

Authors' Note

Coordinator of the RIETE Registry: Dr Manuel Monreal (Spain). RIETE Steering Committee Members: Dr Hervé Decousus (France); Dr Paolo Prandoni (Italy); Dr Benjamin Brenner (Israel). RIETE National Coordinators: Dr Raquel Barba (Spain); Dr Pierpaolo Di Micco (Italy); Dr Laurent Bertoletti (France); Dr Sebastian Schellong (Germany); Dr Manolis Papadakis (Greece); Dr. Inna Tzoran (Israel); Dr Abilio Reis (Portugal); Dr Marijan Bosevski (R.Macedonia); Dr Henri Bounameaux (Switzerland); Dr Radovan Malý (Czech Republic). RIETE Registry Coordinating Center: S & H Medical Science Service. A full list of the RIETE investigators is given in the appendix.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Patores SM. Management of venous thromboembolism in the intensive care unit. *J Crit Care*. 2009;24(2):185-191.
2. Muscedere J, Heyland D, Cook D. Venous thromboembolism in critical illness in a community intensive care unit. *J Crit Care*. 2007;22(4):285-289.
3. Bahloul M, Chaari A, Kallel H, et al. Pulmonary embolism in intensive care unit: predictive factors, clinical manifestations and outcome. *Ann Thorac Med*. 2010;5(2):97-103.
4. Ray W, Strom R, Balckburn S, Ashley W, Sicard G, Rich K. Incidence of deep venous thrombosis after subarachnoid hemorrhage. *J Neurosurg*. 2009;110(5):1010-1014.
5. Khouli H, Shapiro J, Pham V, et al. Efficacy of deep vein thrombosis prophylaxis in the medical intensive care unit. *J Intensive Care Med*. 2006;21(6):352-358.
6. Hamilton M, Yee W, Hull R, Hull R, Ghali W. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. *Neurosurg*. 2011;68(3):571-581.
7. Rogers F, Rebuck J, Sing R. Venous thromboembolism in trauma: an update for the intensive care unit practitioner. *J Intensive Care Med*. 2007;22(1):26-37.
8. Semrad T, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. *J Neurosurg*. 2007;106(4):601-608.
9. Danish S, Burnett M, Ong J, Sonnad S, Maloney-Wilensky E, Stein S. Prophylaxis for deep venous thrombosis in craniotomy patients: a decision analysis. *Neurosurg*. 2005;56(6):1286-1294.
10. Kearon C, Akl EA, Prandoni P, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis. *Chest*. 2012;142(6):1698-1704.
11. Arcelus JJ, Caprini JA, Monreal M, Suárez C, González-Fajardo JA. The management and outcome of acute venous thromboembolism: a prospective Registry including 4011 patients. *J Vasc Surg*. 2003;38(5):916-922.
12. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suárez C, Otero R. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. *J Thromb Haemost*. 2004;2(11):1892-1898.
13. Nieto JA, De Tuesta AD, Marchena PJ, et al. Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective Registry (RIETE). *J Thromb Haemost*. 2005;3(4):703-709.
14. Nieto JA, Bruscas MJ, Ruiz-Ribó D, et al. Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome. *J Thromb Haemost*. 2006;4(11):2367-2372.
15. Nieto JA, Camara T, González-Higueras E, et al. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. *Thromb Haemost*. 2008;100(5):789-796.
16. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*. 1998;339(2):1639-1640.
17. Hamilton M, Yee W, Hull R, Ghali W. Venous thromboembolism prophylaxis in patients undergoing cranial neurosurgery: a systematic review and meta-analysis. *Neurosurgery*. 2011;68(3):571-581.
18. Leon L, Rodriguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The use of prophylactic vena cava filters for high-risk spine surgery. *Ann Vasc Surg*. 2005;19(3):442-447.
19. Raslan A, Fields J, Bhardwaj A. Prophylaxis for venous thromboembolism in neurocritical care: a critical appraisal. *Neurocrit Care*. 2010;12(2):297-309.